If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

Steve Aselage Biography and Net Worth

Director of Acer Therapeutics

Mr. Aselage has more than 30 years of pharmaceutical and biotechnology experience, most recently serving as Chief Executive Officer of Travere Therapeutics (TVTX) (formerly Retrophin, Inc.) from 2014 to 2019. Previously, he was Executive Vice President and Chief Business Officer of BioMarin Pharmaceutical Inc. During his seven years with BioMarin, he built the commercial and medical affairs functions that launched three commercial products and developed commercial businesses in more than 45 countries. Mr. Aselage has also held leadership roles with Cell Therapeutics, Sangstat Medical Corporation, Advanced Tissue Sciences and Genentech. He worked briefly for Genzyme, as well, assisting in the transition following its acquisition of Sangstat. Earlier in his career, he held a variety of sales and sales management positions at companies including Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis) and Bristol Laboratories. Mr. Aselage received his B.S. in Biology from the University of Notre Dame. In addition, Mr. Aselage currently serves on the Advisory Council for the Department of Science at Notre Dame and also serves on the Board of Directors at BioCryst.

What is Steve Aselage's net worth?: The estimated net worth of Steve Aselage is at least $110,189.25 as of May 11th, 2022. Mr. Aselage owns 146,919 shares of Acer Therapeutics stock worth more than $110,189 as of March 31st. This net worth estimate does not reflect any other investments that Mr. Aselage may own. Learn More about Steve Aselage's net worth.
How do I contact Steve Aselage?: The corporate mailing address for Mr. Aselage and other Acer Therapeutics executives is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. Acer Therapeutics can also be reached via phone at (844) 902-6100 and via email at [email protected] Learn More on Steve Aselage's contact information.
Has Steve Aselage been buying or selling shares of Acer Therapeutics?: Steve Aselage has not been actively trading shares of Acer Therapeutics during the last quarter. Most recently, on Thursday, December 9th, Steve Aselage bought 2,016 shares of Acer Therapeutics stock. The stock was acquired at an average cost of $2.15 per share, with a total value of $4,334.40. Learn More on Steve Aselage's trading history.
Are insiders buying or selling shares of Acer Therapeutics?: In the last year, Acer Therapeutics insiders bought shares 1 times. They purchased a total of 819,672 shares worth more than $999,999.84. The most recent insider tranaction occured on November, 29th when CEO Chris Schelling bought 819,672 shares worth more than $999,999.84. Insiders at Acer Therapeutics own 20.2% of the company. Learn More about insider trades at Acer Therapeutics.
Information on this page was last updated on 11/29/2022.

Steve Aselage Insider Trading History at Acer Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/9/2021	Buy	2,016	$2.15	$4,334.40
7/24/2020	Buy	45,000	$3.50	$157,500.00	63,905
7/3/2019	Buy	5,000	$3.72	$18,600.00
12/14/2017	Buy	2,000	$12.00	$24,000.00

Steve Aselage Buying and Selling Activity at Acer Therapeutics

Acer Therapeutics Company Overview

Acer Therapeutics, Inc. is a pharmaceutical company. engages in acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes ACER-001 Edsivo and ACER-2820. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded on March 15, 1991 and is headquartered in Newton, MA.

Today's Range

Now: $0.75

$0.74

$0.77

50 Day Range

MA: $1.83

$0.67

$2.42

2 Week Range

Now: $0.75

$0.65

$4.56

Volume

31,117 shs

Average Volume

445,674 shs

Market Capitalization

$17.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

The Safest Option in Trades!

From Tradewins | Ad

Click here now!